Featured new tests in quarter two of 2025
Featured new tests
In the second quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests including:
- AHPRU | Antihypertension Panel, Random, Urine
- Aids in the management of hypertension, especially treatment resistant hypertension.
- Monitoring compliance in individuals prescribed anti-hypertensive drug therapy.
- As a screen for detecting nonprescribed use of common diuretics
Learn more Anti-hypertensive drug monitoring
John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test can detect antihypertensive medications in urine, providing evidence of whether patients are actually absorbing their medications or whether a new approach might be needed.
Learn more
- MSAES | Overview: Myositis Specific Antibody Evaluation, Serum
- Accurately diagnosing, classifying, and managing idiopathic inflammatory myopathies (IIM) by identifying subtype-specific biomarkers that guide prognosis and treatment.
- Enabling early detection of IIM, particularly in atypical or severe cases, and reducing diagnostic uncertainty for personalized care.
Learn more Focused antibody testing to diagnose, classify disease, and tailor treatment
- NSAIP | Neurosyphilis IgG Antibody Index with VDRL, Serum and Spinal Fluid
- Aids in the diagnosis of neuroinvasive syphilis.
- TRBC3 | T-Cell Receptor Constant Beta Chain (TRBC1) +CD3 Immunostain, Technical Component Only
- Determination of T-cell clonality in T-cell neoplasms.
- TRBC1 | T-Cell Receptor Constant Beta Chain (TRBC1) Immunostain, Technical Component Only
- Determination of T-cell clonality in T-cell neoplasms.
Visit our test catalog for more information on new or updated tests and testing algorithms.
